NEWTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Acer’s patent application No. 16/930,208, exclusively licensed from Assistance Publique—Hôpitaux de Paris, for claims related to certain methods of treating vascular Ehlers-Danlos syndrome (vEDS) with celiprolol. The allowed patent claims in the application titled, “Method of Providing Celiprolol Therapy to a Patient,” include the dosing regimen in Acer’s ongoing Phase 3 DiSCOVER (Decentralized Study of Celiprolol on vEDS-related Event Reduction) clinical trial of EDSIVO™ (celiprolol) for the treatment of patients with COL3A1-positive vEDS.
NEWTON, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Two weeks after the U.S. Food and Drug Administration rejected Acer Therapeutics’ New Drug Application (NDA) for Edsivo (celiprolol), the company initiated a restructuring plan that includes the elimination of 29 employees in order to extend its cash runway through the end of 2020.
Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).
Acer Therapeutics’ bid to repurpose celiprolol — a beta-blocker on the market for hypertension — as a treatment for a rare, inherited connective tissue disorder has hit a severe setback. The Newton, Massachusetts-based company on Tuesday said the FDA rejected the drug and has asked for another clinical trial.
FDA accepted for review NDAs from Acer Therapeutics Inc. (NASDAQ:ACER) and Kala Pharmaceuticals Inc. (NASDAQ:KALA) before the partial government shutdown blocked the agency from taking on new user fee-based applications.
Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical need, today announced the company has closed its Series B round with $8.15 million in new investment. Proceeds from the financing will primarily be used to prepare a new drug application (NDA) for the company’s lead candidate, ACER-002 (celiprolol hydrochloride), which is being developed for the treatment of vascular Ehlers-Danlos Syndrome (vEDS), a rare, life-threatening genetic connective tissue disorder. Acer also plans to use the funds to support manufacturing and clinical development of ACER-001, a proprietary taste-masked, immediate-release formulation of sodium phenylbutyrate (NaPBA) for Maple Syrup Urine Disease (MSUD) and Urea Cycle Disorder (UCD), serious genetic diseases which impact amino acid and ammonia metabolism, respectively.